Albert Einstein College of Medicine

New York University

Victor L Schuster

Yuling Chi

Young-Tae Chang

Jaeki Min

Gary Olson

Andrew Wasmuth

Gary L Olson

Richard S Pottorf

Run Lu

Andrew S Wasmuth

Disclosed are methods and compositions for treating pulmonary arterial hypertension and/or obesity using inhibitors of prostaglandin transporter (PGT) activity.

Treatment of obesity and pulmonary arterial hypertension

The present invention generally relates to prostaglandin transport. More specifically, the invention is directed to compounds that inhibit prostaglandin transport and subsequent COX-2 induction, and methods relating thereto.

Prostaglandin transporter inhibitors

Disclosed are compounds for inhibiting prostaglandin transporter (PGT) activity, pharmaceuticals compositions including the compounds, and methods of treating subjects using the compounds.

Prostaglandin transporter inhibitors and uses thereof

Provided are methods of inhibiting prostaglandin transporter (PGT) activity in mammals. Also provided are methods of determining whether a test compound is an inhibitor of a prostaglandin transporter. Additionally provided are compounds that inhibit prostaglandin transporter activity, and pharmaceutical compositions of those compounds. Methods of inhibiting COX-2 in a mammal are also provided. Additionally, methods of treating pain or inflammation in a mammal are provided.

The present invention provides a purified and isolated nucleic acid encoding human prostaglandin transporter (hPGT). The present invention also provides a vector comprising a nucleic acid encoding human prostaglandin transporter (hPGT), a cell stably transformed with this vector, as well as a method for producing a recombinant, human prostaglandin transporter (hPGT). The present invention also provides a purified and isolated human prostaglandin transporter (hPGT), and an antibody immunoreactive with this protein. The present invention further provides a method for evaluating the uptake of a selected prostaglandin by cells expressing nucleic acid encoding human prostaglandin transporter (hPGT). Finally, the present invention provides a vector and an embryonic stem cell each of which comprises nucleic acid encoding a mutant human prostaglandin transporter (hPGT), a non-human transgenic animal whose germ and somatic cells contain nucleic acid encoding a mutant human prostaglandin transporter (hPGT) introduced into said animal, or an ancestor thereof, at an embryonic stage, as well as a method for producing the non-human, transgenic animal.

Growing community of inventors

New York, NY, United States of America

Victor L Schuster